Baxter International Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 09/25/2023

Stock Rating
17
Price Target
$58.00
Consensus
Outperform
Upside
54.67%
Analysts
6
Stock Rating
17
Upside
54.67%
Analysts
6
Price Target
$58.00

Baxter International Inc Stock Forecast and Price Target

Baxter International Inc's most recent price target of $58.00 for 2023 was provided by six renowned analysts over the past few months, with an average prediction of $58.00. If this prediction is correct, Baxter International Inc's stock could rise by 54.67 percent from its current trading price. The potential increase for the stock is $58.00 per share, with a possible range of $51.00 to $85.00. If you're thinking of investing in BAX stock, it might be good to look at its rivals too.

$58.00

54.67% Upside

Outperform
Outperform

Baxter International Inc Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Baxter International Inc has seen a decline in its Price, from $83.41 to $0.00 – a 100.00% decrease. Next year, analysts are expecting Fair Value to reach $122.72 – an increase of 100.00%. Over the next eight years, the forecast is for Fair Value to grow by 100.00%.

2023 Fair Value Forecast
$122.72
2024 Fair Value Forecast
$138.60
2025 Fair Value Forecast
$152.71
2026 Fair Value Forecast
$165.56
2027 Fair Value Forecast
$111.89
2028 Fair Value Forecast
$123.44
2029 Fair Value Forecast
$136.13
2030 Fair Value Forecast
$149.42
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly & Co Outperform 14
$552.32 Buy/Sell $333.19 -27.58%
JNJ Stock Forecast Johnson & Johnson Outperform 10
$160.26 Buy/Sell $179.95 12.63%
PFE Stock Forecast Pfizer Inc Outperform 3
$32.98 Buy/Sell $44.13 59.64%
MRK Stock Forecast Merck Outperform 5
$105.84 Buy/Sell $99.57 11.49%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$59.16 Buy/Sell $80.99 40.30%

Baxter International Inc Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Baxter International Inc's Revenue has grown from $11.36B to $15.11B – a 33.01% increase. Next year, analysts are expecting Revenue to reach $16.65B – an increase of 10.16%. Over the next eight years, the forecast is for Revenue to grow by 22.22%.

2023 Rev Forecast
$16.65B
2024 Rev Forecast
$17.41B
2025 Rev Forecast
$18.32B
2026 Rev Forecast
$19.31B
2027 Rev Forecast
$18.08B
2028 Rev Forecast
$17.88B
2029 Rev Forecast
$18.05B
2030 Rev Forecast
$18.47B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 13
$350.67 Buy/Sell $384.26 -7.04%
ZTS Stock Forecast Zoetis Inc Outperform 18
$177.72 Buy/Sell $209.70 15.35%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$834.64 Buy/Sell $796.73 -6.31%

Baxter International Inc Dividend per Share Forecast for 2023 - 2025 - 2030

In the last three years, Baxter International Inc's Dividend per Share has grown by 36.47%, rising from $0.85 to $1.16. For next year, analysts predict Dividend per Share of $1.31, which would mean an increase of 12.93%. Over the next eight years, experts predict that Baxter International Inc's Dividend per Share will grow at a rate of 45.57%.

2023 DPS Forecast
$1.31
2024 DPS Forecast
$1.39
2025 DPS Forecast
$1.72
2026 DPS Forecast
$1.92
2027 DPS Forecast
$1.29
2028 DPS Forecast
$1.37
2029 DPS Forecast
$1.52
2030 DPS Forecast
$1.69
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$170.77 Buy/Sell $244.18 46.98%
VTRS Stock Forecast Viatris Inc Hold 8
$9.71 Buy/Sell $13.70 39.03%
UTHR Stock Forecast United Therapeutics Corp Outperform 12
$224.06 Buy/Sell $280.69 31.66%

Baxter International Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

Baxter International Inc's Free Cash Flow has decreased In the last three years, from $1.41B to $-1812.00T – a 128693334.59% drop. In the following year, 1 experts forecast Baxter International Inc's Free Cash Flow will decrease by 100.00%, to $2.10B. In 2030, professionals predict that Baxter International Inc's Free Cash Flow will decrease by 100.00%, to $3.01B.

2023 FCF Forecast
$2.10B
2024 FCF Forecast
$2.55B
2025 FCF Forecast
$3.34B
2026 FCF Forecast
$3.29B
2027 FCF Forecast
$2.33B
2028 FCF Forecast
$2.48B
2029 FCF Forecast
$2.78B
2030 FCF Forecast
$3.01B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CTLT Stock Forecast Catalent Inc Hold 15
$45.82 Buy/Sell $83.92 59.32%
IONS Stock Forecast Ionis Pharmaceuticals Inc Outperform 9
$42.67 Buy/Sell $52.42 17.18%
BCPC Stock Forecast Balchem Outperform 18
$126.67 Buy/Sell $163.67 29.47%

Baxter International Inc Net Income Forecast for 2023 - 2025 - 2030

In the last three years, Baxter International Inc's Net Income has fallen from $1.00B to $-2.42B – a 341.86% decrease. According to 14 prominent analysts, Baxter International Inc's Net Income will fall by 202.07% in the next year, reaching $2.47B. By 2030, professionals believe that Baxter International Inc's Net Income will decrease by 224.69%, reaching $3.02B – a concerning trend for the company.

2023 NI Forecast
$2.47B
2024 NI Forecast
$2.81B
2025 NI Forecast
$3.09B
2026 NI Forecast
$3.34B
2027 NI Forecast
$2.22B
2028 NI Forecast
$2.47B
2029 NI Forecast
$2.74B
2030 NI Forecast
$3.02B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
NEOG Stock Forecast Neogen Hold 16
$19.48 Buy/Sell $37.00 30.90%
CYTK Stock Forecast Cytokinetics Inc Outperform 10
$30.00 Buy/Sell $62.67 100.00%
TGTX Stock Forecast TG Therapeutics Outperform 9
$8.97 Buy/Sell $73.38 111.82%

Baxter International Inc EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Baxter International Inc's EBITDA has seen a drop from $2.61B to $2.37B – a 9.17% decrease. In the next year, analysts believe that EBITDA will reach $4.16B – an increase of 75.93%. For the next eight years, experts predict that Baxter International Inc's EBITDA will grow at a rate of 102.04%.

2023 EBITDA Forecast
$4.16B
2024 EBITDA Forecast
$4.34B
2025 EBITDA Forecast
$4.68B
2026 EBITDA Forecast
$5.06B
2027 EBITDA Forecast
$4.74B
2028 EBITDA Forecast
$4.61B
2029 EBITDA Forecast
$4.64B
2030 EBITDA Forecast
$4.78B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
INDV Stock Forecast Indivior PLC Buy 14
£21.51 Buy/Sell £3.79 -77.96%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$32.82 Buy/Sell $79.67 137.66%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$32.32 Buy/Sell $0.00 -8.73%

Baxter International Inc EBIT Forecast for 2023 - 2025 - 2030

Baxter International Inc's EBIT has seen impressive growth In the last two years, rising from $1.82B to $2.09B – a growth of 14.76%. In the next year, analysts believe that EBIT will reach $3.37B – an increase of 61.10%. For the next eight years, the forecast is for EBIT to grow by 88.97%.

2023 EBIT Forecast
$3.37B
2024 EBIT Forecast
$3.69B
2025 EBIT Forecast
$4.00B
2026 EBIT Forecast
$4.35B
2027 EBIT Forecast
$3.33B
2028 EBIT Forecast
$3.49B
2029 EBIT Forecast
$3.70B
2030 EBIT Forecast
$3.95B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$45.96 Buy/Sell $41.00 -4.26%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$8.53 Buy/Sell $12.60 46.54%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$30.06 Buy/Sell $35.50 13.11%

Baxter International Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, Baxter International Inc has seen a decline in its EPS, from $3.31 to $-4.83 – a 245.92% decrease. According to the 16 analysts polled, in the next year, Baxter International Inc's EPS will fall by 200.83%, reaching $4.87. By 2030, professionals believe that Baxter International Inc's EPS will have decreased by 222.76%, falling to $5.93.

2023 EPS Forecast
$4.87
2024 EPS Forecast
$5.50
2025 EPS Forecast
$6.06
2026 EPS Forecast
$6.57
2027 EPS Forecast
$4.44
2028 EPS Forecast
$4.90
2029 EPS Forecast
$5.40
2030 EPS Forecast
$5.93
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$58.86 Buy/Sell $195.43 169.28%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$150.96 Buy/Sell $170.08 15.92%
USNA Stock Forecast USANA Health Sciences Hold 14
$59.75 Buy/Sell $104.00 -4.60%